(5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide methanesulfonate | 934240-35-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide methanesulfonate
• 英文别名: (5R)-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide methanesulfonate；Raxatrigine mesylate；(2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide;methanesulfonic acid
• CAS: 934240-35-4
• 化学式: CH₄O₃S*C₁₈H₁₉FN₂O₂
• 分子量: 410.466
• InChiKey: ZSMXMVUVWUFIPK-PPPUBMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.19
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  127
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (5R)-5-(4-{[(2-氟苯基)甲基]氧基}苯基)-L-脯氨酰胺 在 甲烷磺酸 作用下， 以 乙酸乙酯 为溶剂， 反应 48.0h， 生成 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide methanesulfonate
  参考文献：
  名称：

  WO2007/42239

  摘要：

  公开号：

文献信息

• NOVEL COMPOUNDS
  申请人：Alvaro Giuseppe

  公开号：US20110098335A1

  公开（公告）日：2011-04-28

  The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels.

  本发明提供了一种式（I）的化合物，其溶剂化物、盐或前药，在调节使用依赖性电压门控钠通道介导的疾病和病症治疗中有用。
• PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS
  申请人：Alvaro Giuseppe

  公开号：US20090318530A1

  公开（公告）日：2009-12-24

  The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker compound of formula (I) wherein R 1 and R 2 are independently hydrogen, C 1-6 alkyl or C 3-6 cycloalkylC 1-6 alkyl; or R 1 and R 2 , together with the nitrogen to which they are attached, may form an unsubstituted 3-, 4-, 5- or 6-membered saturated ring; q is 1 or 2; R 3 and R 4 are hydrogen; or when q is 1, R 3 and R 4 , together with the interconnecting atoms, may form a cyclopropane ring; X is carbon or nitrogen; n is 0, 1 or 2, wherein when present each R 5 is independently selected from the list consisting of C 1-3 alkyl, halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy; and either R 6 or R 7 is —O—R 8 or —OCH 2 R 8 , wherein the other R 6 or R 7 is hydrogen or R 5 ; and wherein R 8 is either a phenyl ring or a 5- or 6-membered aromatic heterocyclic ring (independently containing one or more nitrogen, sulphur or oxygen atoms) wherein either the phenyl ring or the heterocyclic ring is optionally substituted by one or more groups independently selected from the list consisting of C 1-3 alkyl, halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy; or a pharmaceutically acceptable salt or solvate thereof; as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including epilepsy and mood disorders.

  本发明涉及一种药物组合物，包括NK1受体拮抗剂和式(I)的钠通道阻滞剂化合物，其中R1和R2独立地为氢、C1-6烷基或C3-6环烷基C1-6烷基；或者R1和R2连同它们所连接的氮原子可以形成未取代的3、4、5或6成员饱和环；q为1或2；R3和R4为氢；或者当q为1时，R3和R4连同相互连接的原子可以形成环丙烷环；X为碳或氮；n为0、1或2，其中当存在时，每个R5独立地从C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的列表中选择；且R6或R7为—O—R8或—OCH2R8，另一个R6或R7为氢或R5；其中R8为苯环或5-或6-成员芳香杂环环（独立地包含一个或多个氮、硫或氧原子），其中苯环或芳香杂环环中的任一环都可以选择一个或多个独立的基团进行取代，所述基团从C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的列表中独立选择；或其药学上可接受的盐或溶剂；作为同时或顺序给药的联合制剂，并且将这种组合物用于治疗某些疾病，包括癫痫和情感障碍。
• Novel Compounds
  申请人：Alvaro Giuseppe

  公开号：US20080280969A1

  公开（公告）日：2008-11-13

  The invention provides a compound of formula (I), pharmaceutical compositions thereof, and methods of treatment using the same.

  本发明提供了化合物公式(I)、其制药组合物以及使用它们的治疗方法。
• PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1
  申请人：Alvaro Giuseppe

  公开号：US20100105688A1

  公开（公告）日：2010-04-29

  The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker, wherein at least one of them is at subtherapeutic dose, as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.

  本发明涉及一种制药组合物，包括NK1受体拮抗剂和钠通道阻滞剂，其中至少一种剂量为亚治疗剂量，作为同时或顺序给药的联合制剂，并且本发明还涉及在治疗某些疾病，包括癫痫、情绪障碍和疼痛方面使用这种组合物的方法。
• 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY
  申请人：Alvaro Giuseppe

  公开号：US20100105754A1

  公开（公告）日：2010-04-29

  The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels.

  本发明提供了化合物(I)、其溶剂化物、盐或前药，用于治疗通过调节使用依赖性电压门控钠通道介导的疾病和症状。